200 related articles for article (PubMed ID: 36688995)
1. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
[TBL] [Abstract][Full Text] [Related]
2. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
6. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
[TBL] [Abstract][Full Text] [Related]
7. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
Jureczek J; Bergmann R; Berndt N; Koristka S; Kegler A; Puentes-Cala E; Soto JA; Arndt C; Bachmann M; Feldmann A
Sci Rep; 2019 Jul; 9(1):10547. PubMed ID: 31332252
[TBL] [Abstract][Full Text] [Related]
8. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract][Full Text] [Related]
9. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
10. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
11. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
[TBL] [Abstract][Full Text] [Related]
12. Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab
Jureczek J; Feldmann A; Bergmann R; Arndt C; Berndt N; Koristka S; Loureiro LR; Mitwasi N; Hoffmann A; Kegler A; Bartsch T; Bachmann M
Onco Targets Ther; 2020; 13():5515-5527. PubMed ID: 32606767
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
14. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
Bachmann M
Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
[TBL] [Abstract][Full Text] [Related]
15. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
Arndt C; Loureiro LR; Feldmann A; Jureczek J; Bergmann R; Máthé D; Hegedüs N; Berndt N; Koristka S; Mitwasi N; Fasslrinner F; Lamprecht C; Kegler A; Hoffmann A; Bartsch T; Köseer AS; Egan G; Schmitz M; Hořejší V; Krause M; Dubrovska A; Bachmann M
Oncoimmunology; 2020; 9(1):1743036. PubMed ID: 32426176
[TBL] [Abstract][Full Text] [Related]
16. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
17. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
18. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Uherek C; Tonn T; Uherek B; Becker S; Schnierle B; Klingemann HG; Wels W
Blood; 2002 Aug; 100(4):1265-73. PubMed ID: 12149207
[TBL] [Abstract][Full Text] [Related]
19. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer.
Wu X; Huang S
Bull Cancer; 2019 Nov; 106(11):946-958. PubMed ID: 31711572
[TBL] [Abstract][Full Text] [Related]
20. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]